French drugmaker Sanofi has ended a licensing pact with MannKind for the rights to sell Afrezza, saying the insulin inhaler for diabetes care was unlikely to reach even the lowest patient levels anticipated.
from WSJ.com: US Business http://ift.tt/1SeLIsc
via IFTTT
No comments:
Post a Comment